Bioaroundworld March Interview - Joan Shen
"Female leader in Global Biotech Industry and Cross Region Develop Collaboration"
Co-hosted by Bioaroundworld and MSQ Ventures
Tuesday, March 8, 2022
9:00AM - 10:00AM EST
https://us02web.zoom.us/j/85114345416
Zoom Webinar ID : 85114345416
About Speaker:
Joan Shen(申华琼) MD, PhD
Founder and Chief Executive Officer
NeuShen Therapeutics
Endpoints News: one of the 20 women in Biopharma R&D honorees 2021
Forbes: Top 50 Women in Tech in China 2021
Joan obtained PhD in life science and is a licensed physician with board certification in Psychiatry. She had postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. Being responsible for CNS global clinical development programs cross phase 1-4, she worked in Eli Lilly & Co, Wyeth and Pfizer in US, and gained extensive experiences of working with FDA, EMEA, CFDA, PMDA, KFDA and etc.
Joan was sent by Pfizer in 2011 as the China Clinical Head. She later joined Hengrui Pharmaceutical as the CMO. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China Development Head in 2015, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Joan joined I-Mab Biopharma as the Head of R&D initially and was promoted to CEO afterwards. During her tenure, I-Mab was successfully listed on Nasdaq and formed a CD47 alliance with AbbVie with lemzoparlimab. She took the new adventure by starting up NeuShen Therapeutics, a company focusing on CNS drug development, at the beginning of 2022.
Joan was selected by Endpoints News as one of the 20 women in Biopharma R&D honorees 2021 and was listed as Forbes top 50 Women in Tech in China 2021.
Interview Highlights:
How a Chinese female Phd has been transferred to be a leader of global biotech industry and a pioneer of cross region drug develop collaboration
How Joan developed her global clinical trial knowledge and experience by working with FDA, EMEA, CFDA, PMDA, KFDA at Eli Lily & Co, Wyeth and Pfizer
How Joan led a China biotech company, I-Mab, to list on Nasdaq which became a leading global innovative drug developer
What Joan's vision for her new venture, NeuShen Therapeutics